Background {#Sec1}
==========

Bilateral macronodular adrenal hyperplasia (BMAH) is a rare type of Cushing's syndrome (CS) that accounts for less than 1% of all endogenous CS cases \[[@CR1]\]. BMAH is characterized by bilateral enlargement of the adrenal glands, with adrenocortical nodule diameters larger than 10 mm and frequently closer to 30 or 40 mm. Patients with BMAH also present with abnormal cortisol production and reduced expression of steroidogenic enzymes and Melanocortin type 2 receptor (MC2R) \[[@CR2]\]. Usually, the disease progresses slowly, and patients are diagnosed between 40 and 60 years old only after they present with CS and suppressed circulating corticotropin levels \[[@CR3]\]. One potential reason for the slow disease progression is that increased overall cortisol production only occurs when the patients have developed large adrenal nodules \[[@CR3]\]. Indeed, most BMAH patients are identified while investigating for an incidentally discovered bilateral adrenal lesion. Importantly, the bilateral appearance of the nodules raised the hypothesis of an underlying germline genetic predisposition. Although most cases appear sporadic, familial cases are well documented, indicating a potential major genetic component of the disease \[[@CR4]\].

Many familial cases of BMAH are associated with mutations in *ARMC5*, a putative tumor suppressor gene, which are thought to underlie this form of the disorder \[[@CR3]\]. About 45--55% of BMAH cases are thought to be associated with the variations in ARMC5 \[[@CR3], [@CR5]\]. These mutations inactivate *ARMC5* and slowly induce dedifferentiation of adrenocortical cells and growth of bilateral masses. *ARMC5*-mutant patients also present with a more severe disease than wild-type patients. Specifically, in the mutated group, the age of diagnosis is lower, while the prevalence of clinical CS and hypertension, the total adrenal weights, and the number of nodules are all higher \[[@CR4]\].

Inactivation of ARMC5 in BMAH follows the "two-hit" model of a tumor suppressor gene responsible for a hereditary neoplasia syndrome. BMAH patients have a single germline mutation in ARMC5 leading to the expression of an inactive mutant protein, acting as the first 'hit'; however, the other allele could encode for the protein. The BMAH would happen only if the other allele suffered another subsequent somatic mutation which resulted in the absence of the protein and causing the development of nodules and overproduction of cortisol \[[@CR6]\]. Moreover, tumors caused by mutations in *ARMC5* are likely to be polyclonal, because both alleles of *ARMC5* carry mutations at both the somatic and germline levels. Therefore, different nodules on the same adrenal gland may carry different variations of the *ARMC5* gene \[[@CR7]\]. In this study, we present a patient with BMAH induced by a novel heterozygous germline *ARMC5* mutation (c. 517C \> T, p. Arg173\*) alone rather than the previously hypothesized two-hit somatic mutation.

Case presentation {#Sec2}
=================

A 51-year-old woman was admitted to our department for 2 months to identify masses in the bilateral adrenals. Physical examination revealed typical Cushingoid features, including a full moon face, central obesity, and purple striae of the bilateral axillary and lower abdomen.

Upon admission, the hormonal work-up revealed hypercortisolism both in the morning and late at night. Specifically, 8:00 morning serum cortisol levels were 604 nmol/L (normal range: 50-280 nmol/L) and 24:00 levels were 443 nmol/L (normal range: 10-120 nmol/L) (Table [1](#Tab1){ref-type="table"}). Plasma ACTH levels were normal at both time points, at 11.72 pg/mL (normal range: 5.08-32.8 pg/mL) and 12.27 pg/mL (normal range: 5-15 pg/mL), for morning and night levels, respectively. The results of low- and high-dose dexamethasone suppression tests were negative, indicating the latter mentioned adrenal masses were corticotropin independent. Levels of other hormone were also abnormal, including Thyroxine (T4): 41.83 nmol/L (normal range: 78.38-157.4 nmol/L) and free T4: 5.16 pmol/L (normal range: 7.84-20.1 pmol/L), while estradiol, testosterone, FSH (follicle-stimulating hormone), LH (luteinizing hormone), growth hormone, thyrotropin (TSH), and prolactin (PRL) levels were all normal.Table 1Patient hormone expression profileHormone (reference range)On first admissionAfter left adrenalectomyOn second admissionCortisol 8, ng/mL (50--280 ng/mL)604244217Cortisol 16, ng/mL (20--140 ng/mL)361294252Cortisol 24, ng/mL (10--120 ng/mL)443273281ACTH 8, pg/mL (5.08--32.8 pg/mL)11.727.217.06ACTH 16, pg/mL (10.7--30.5 pg/mL)9.259.1710.44ACTH 24, pg/mL (5--15 pg/mL)12.279.255.25Vanillylmandelic acid, μmol/24 h (9.6-50.0 μmol/24 h urine)23.40--29.8017-hydroxycorticosteroid, μmol/24 h (5.5-33.2 μmol/24 h urine)14.30--15.8017-ketosteroid, μmol/24 h (13.9-76.3 μmol/24 h urine)43.90--52.70Orthostatic renin activity, ng/mL/h (0.33-5.15 ng/mL/h)5.96--9.19Clinostatic renin activity, ng/mL/h (0.07-1.51 ng/mL/h)2.25--15.88Thyroxine, T4, nmol/L (78.38-157.4 nmol/L)41.83----Free thyroxine, nmol/L (7.86-20.1 nmol/L)0.1----Abbreviations: *ACTH* adrenocorticotropic hormone

Adrenal computed tomography (CT) revealed bilateral adrenal masses (left: 3.2\*2.4 cm and right: 2.2\*2.1 cm) (Fig. [1a](#Fig1){ref-type="fig"} and [b](#Fig1){ref-type="fig"}), while chest CT revealed an old right rib fracture. Pituitary magnetic resonance imaging (MRI) was normal, whereas vertebral MRI revealed a compression fracture of the thoracolumbar spine (T7 and L3).Fig. 1Results of imaging, histopathology, and DNA sequencing. **a** and **b** Adrenal computed tomography scan revealed bilateral adrenal masses (indicated by red arrows). **c** and **d** Hematoxylin and eosin staining of the adrenal tissue revealed nodular hyperplasia. **e**. Sequencing of DNA extracted from peripheral leukocytes identified a novel heterozygous germline *ARMC5* mutation, c. 517C \> T, p. Arg173\*. (indicated by red arrows)

On January 19th, 2016, the patient underwent a left adrenalectomy using the retroperitoneal laparoscopic procedure. Surgically removed adrenal glands demonstrated nodular hyperplasia without hemorrhage or infarction, and histopathology substantiated the BMAH diagnosis (Fig. [1c](#Fig1){ref-type="fig"} and [d](#Fig1){ref-type="fig"}).

Precise isolation of the tumor specimen during the sample collection was conducted with the help of the H&E staining. Using WES (whole-exome sequencing) of the germline and tumor DNA, we first identified a novel heterozygous germline *ARMC5* mutation (c. 517C \> T, p. Arg173\*, chr16: 31473284) that resulted in a premature translational-termination codon. This nonsense mutation would impair the function of ARMC5. The *ARMC5* variants identified by WES were validated by Sanger sequencing of the germline DNA (Fig. [1e](#Fig1){ref-type="fig"}). We then performed segregation analysis of the variants. All coding exons of *ARMC5* in the patient were sequenced, and then this sequence was analyzed using Mutation Surveyor version 2.51 (SoftGenetics LLC) with comparison to the reference sequence in GenBank ([http://www.ncbi.nlm.nih.gov/genbank/](http://www.ncbi.nlm.nih.gov/genbank)) Subsequently, we conducted WES of the tumor specimen compared to matched normal DNA and identified 79 somatic single nucleotide polymorphisms (SNPs)/insertion-deletion (indel) mutations, including 32 missense/nonsense/splice/stop-loss mutations (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Among these, In silico analysis predicted no known CS-related mutations. The CARE guidelines were followed when reporting this case.

Discussion and conclusion {#Sec3}
=========================

In this study, we reported a rare case of BMAH in which the patient presented with the typical bilateral adrenal macronodular hyperplasia, BMAH-associated CS, and hypertension. In this unique case of BMAH, the sequencing results identified a novel heterozygous germline *ARMC5* mutation (c. 517C \> T, p. Arg173\*).

As these adrenal nodules inefficiently produce cortisol, a clinical syndrome only becomes apparent with large nodules. Previous studies predicted that this form of BMAH becomes clinically apparent only with a second somatic mutation in addition to *ARMC5*, as described in Knudson's two-hit model \[[@CR3]\]. In these cases, *ARMC5* would bear a first germline mutation and a second somatic mutation within the adrenals, resulting in a loss of protein function and subsequent tumor formation \[[@CR8]\]. However, in this case, BMAH development did not seem to require a second mutation. The patient presented with only a heterozygous germline *ARMC5* mutation (c. 517C \> T, p. Arg173\*), and no mutations of the other allele or of CS-related genes in the bilateral adrenal tissues. This single germline *ARMC5* mutation is not entirely surprising, as Zilbermint et al. previously reported a heterozygous germline *ARMC5* mutation with no additional somatic inactivating events in *ARMC5* exons, such as loss of heterozygosity \[[@CR7]\]. This cast doubt on the pathogenic role of heterozygous *ARMC5* mutations in primary aldosteronism. Our results suggest that *ARMC5*-induced BMAH does not require additional somatic mutations, which was consistent with the haploinsufficient model \[[@CR9]\]. The combination of high-frequency LOH and rare point mutations has led to the suggestion that *ARMC5* might demonstrate haploinsufficiency (absent or reduced function due to the loss or inactivation of a single allele), just as *CDKN1B* described by A. J. W. Paige \[[@CR9]\]. However, this needs to be further substantiated. Of course, similar to Correa et al. \[[@CR10]\], we cannot not exclude the possibility that other larger genomic losses or the changes of the methylation, as well as structural alterations including inversions and copy number changes might exist that were not detected by the methods used in this study.

BMAH is a heterogeneous disease with varying degrees of hypercortisolism (from subclinical to overt CS), radiological aspects (from massive nodular hyperplasia to macronodular adrenal hyperplasia), and illegitimate receptors \[[@CR11]\]. The presence or absence of *ARMC5* mutations may be associated with these diverse phenotypes. Previous studies have shown that ARMC5 defects are associated with a more severe disease, such as higher cortisol levels, larger adrenal glands and higher numbers of nodules \[[@CR3], [@CR5]\]. In addition, ARMC5-mutated patients have hypertension more often than WT (wild type) patients \[[@CR12]\]. However, one important consideration is that even if there is a connection between BMAH and *ARMC5* mutations, the resulting phenotypes would vary with the nature of the mutations. For example, Elbelt el al. \[[@CR13]\] reported that somatic (p.R502fs) and germline frame shift *ARMC5* mutations (c.323_324insC, p.A110fs\*9) are associated with intracranial meningioma, while other family members lacking the somatic mutation did not develop the disease. This indicates that specific *ARMC5* mutations are associated with unique disease phenotypes. In the current study, the heterozygous germline *ARMC5* mutation (c. 517C \> T, p. Arg173\*) alone was potentially associated with younger age at diagnosis, BMAH, CS, and hypertension.

In conclusion, we have identified a novel germline *ARMC5* mutation (c. 517C \> T, p. Arg173\*) in a sporadic case of BMAH characterized with bilateral adrenal macronodular hyperplasia, BMAH-associated CS, and hypertension. Identification of this genotype-phenotype relationship increases our knowledge regarding the development of BMAH and the connection to ARMC5. Determining patient *ARMC5* status might enhance BMAH diagnosis, and screening family members for *ARMC5* mutations may enable clinicians to identify BMAH earlier and prevent patient morbidity and mortality.

Additional file
===============

 {#Sec4}

Additional file 1**: Table S1.** Identified 79 somatic single nucleotide polymorphisms (SNPs)/insertion-deletion (indel) mutations. Whole-exome sequencing of the tumor specimen compared to matched normal DNA was conducted and 79 somatic single nucleotide polymorphisms (SNPs)/insertion-deletion (indel) mutations were identified, including 32 missense/nonsense/splice/stop-loss mutations (XLSX 24 kb)
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